Cited by 80Childhood Cancer Survivors' Quality of LifeTelomeres, Telomerase, and SenescenceFrailty in Older Adults

Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty

Open access
Smitherman, Andrew B., Wood, William A., Mitin, Natalia, Ayer Miller, Vanessa L., Deal, Allison M., Davis, Ian J., Blatt, Julie, Gold, Stuart H. +1 more·2020·Cancer

Abstract

Background Cellular senescence, measured by expression of the cell cycle kinase inhibitor p16INK4a, may contribute to accelerated aging in survivors of childhood, adolescent, and young adult cancer. The authors measured peripheral blood T‐lymphocyte p16INK4a expression among pediatric and young adult cancer survivors, hypothesizing that p16INK4a expression is higher after chemotherapy and among frail survivors. Methods A cross‐sectional cohort of young adult survivors and age‐matched, cancer‐free controls were assessed for p16INK4a expression and frailty. Newly diagnosed pediatric patients underwent prospective measurements of p16INK4a expression before and after cancer therapy. Frailty was measured with a modified Fried frailty phenotype evaluating sarcopenia, weakness, slowness, energy expenditure, and exhaustion. Results The cross‐sectional cohort enrolled 60 survivors and 29 age‐matched controls with a median age of 21 years (range, 17‐29 years). The prospective cohort enrolled 9 newly diagnosed patients (age range, 1‐18 years). Expression of p16INK4a was higher among survivors compared with controls (9.6 vs 8.9 log2 p16 units; 2‐sided P = .005, representing a 25‐year age acceleration in survivors) and increased among newly diagnosed patients from matched pretreatment to posttreatment samples (7.3‐8.9 log2 p16 units; 2‐sided P = .002). Nine survivors (16%) were frail and had higher p16INK4a expression compared with robust survivors (10.5 [frail] vs 9.5 [robust] log2 p16 units; 2‐sided P = .055), representing a 35‐year age acceleration among frail survivors. Conclusions Chemotherapy is associated with increased cellular senescence and molecular age in pediatric and young adult cancer survivors. Frail survivors, compared with robust survivors, exhibit higher levels of p16INK4a, suggesting that cellular senescence may be associated with early aging in survivors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.33112

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ageing exacerbates the toxicity of anticancer treatments, and some treatments can accelerate the onset of age-related dysfunctions, rendering chemotherapy a potential inducer of premature ageing via induction of senescence and SASP.

    “Ageing exacerbates the toxicity of these treatments and, in addition, some of them can also accelerate the onset of age-related dysfunctions, rendering chemotherapy a potential inducer of premature ageing via induction of senescence and SASP 193,194 .”

    From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [193]

    The Introduction and Discussion (page numbers unavailable) link cytotoxic chemotherapy to increased p16 expression, cellular senescence, and accelerated molecular aging in young cancer survivors. The copy does not establish that aging exacerbates treatment toxicity or that SASP mediates chemotherapy-related premature aging. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Childhood cancer survivors have premature accumulation of T lymphocytes expressing high levels of p16 INK4a and have higher circulating concentrations of the pro-inflammatory SASP factors IL-10 and IL-17.

    “Childhood cancer survivors have premature accumulation of T lymphocytes expressing high levels of p16 INK4a and have higher circulating concentrations of the pro- inflammatory SASP factors IL-10 and IL-17 (refs. 193,197 ) .”

    From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [193]

    The Results report higher p16INK4a expression in peripheral blood T lymphocytes from young adult survivors of childhood, adolescent, and young adult cancers than in age-matched controls. The paper measures expression, not an accumulation of p16-high T cells, and the passages found do not report circulating IL-10 or IL-17 concentrations (searched: IL-10, IL-17, and interleukins). Page numbers were not available in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • There is strong evidence for increased senescence and accelerated aging in childhood cancer survivors treated with chemotherapies.

    “In addition to studying the senotherapeutic effects of exercise in older adults, there is strong evidence for increased senescence and accelerated aging in childhood cancer survivors treated with chemotherapies (69).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 25 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Smitherman, A. B., Wood, W. A., Mitin, N., Ayer Miller, V. L., Deal, A. M., Davis, I. J., Blatt, J., Gold, S. H., & Muss, H. B.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Sapere Bio Research Triangle Park North Carolina
  • Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill North Carolina
Corresponding author
Smitherman, Andrew B.
Venue
Cancer
Publisher
Wiley
Published
2020-08-24
Volume
126
Issue
22
Pages
4975-4983
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W3081212722
Cited by
80
References
25
Citations by year
2026: 13 · 2025: 9 · 2024: 17 · 2023: 12 · 2022: 17 · 2021: 9 · 2020: 2
FWCI
9.59
Type
journal article
Language
en
Open access
Locations
  • Cancer (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (R01‐CA203023)
  • North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill (KL2‐TR002490)
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
Keywords
accelerated aging, childhood cancer survivors, adolescent cancer survivors, young adult cancer survivors, p16INK4a, cellular senescence, frailty, chemotherapy, T cells, Fried frailty phenotype, childhood cancer
MeSH terms
Cancer Survivors, Frailty, Adolescent, Adult, Aging, Cross-Sectional Studies, Humans, Cyclin-Dependent Kinase Inhibitor p16, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review